Project Grant R21AI203697
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $297K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78227, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Texas Biomedical Research Institute $927,025 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate IL-21-IGFC therapy for enhancing pulmonary immune reconstitution and limiting viral persistence in co-infected macaques. The research addresses incomplete immune reconstitution in individuals co-infected with HIV and tuberculosis despite antiretroviral therapy, using an established...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded $824,278 to Texas Biomedical Research Institute on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for Project Grant R01AI201766. The award funds comparative investigation of bacterial antigen presentation mechanisms in Mycobacterium tuberculosis and Francisella tularensis infections to...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $828,340 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate HIV-1 transcription reactivation mechanisms in latent reservoir cells. The research explores the role of transcription factors and Tat protein in initiating and sustaining HIV-1 transcription reactivation, using genetic and genomic approaches to examine HIV-1...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of convergent RNA polymerase II transcription in HIV-1 latency and reactivation. The research aims to define how convergent POL II transcription—specifically antisense and downstream forms originating from the 5'-LTR—regulates sense HIV-1 transcription...
- The National Institute of Allergy and Infectious Diseases awarded the University of Texas Medical Branch at Galveston $294,150 on August 1, 2026, for research on defective pro-viruses and viral proteins in neuroHIV and HIV cure strategies under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research employs correlative microscopy (live-cell, confocal, and electron microscopy), mass spectrometry imaging, and spatial proteomic and mRNA analysis to detect, quantify, and...
- The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded the Scripps Research Institute $937,343 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research optimizing vaccine-elicited cross-neutralizing antibody responses targeting the HIV envelope (Env) trimer apex to inform broadly neutralizing antibody (BnAb) development for...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $253,256 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model through May 31, 2028. The project develops a preclinical platform for engineered B cell therapies aimed at creating a functional HIV cure. Scripps will determine whether immunoglobulin heavy chain...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $804,464 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research targeting the super elongation complex to regulate HIV transcription and latency. The research addresses HIV persistence in long-lived latent reservoirs that remain a major barrier to functional cure. The project focuses on developing small molecule regulators of viral transcription as...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded San Diego Biomedical Research Institute $809,479 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered native HIV envelope glycoprotein trimers that induce broadly neutralizing antibodies (BNAbs) targeting the CD4-binding site. The research addresses two critical limitations in current HIV-1 vaccine strategies. First, existing boosting immunogens lack the stringency...